Fig. 1From: Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaSerum levels of interleukin-17 (IL-17) in patients treated with neoadjuvant ipilimumab correlate Gr3 diarrhea/colitis when tested at baseline (p = 0.02) and at week 6 (p = 0.06)Back to article page